{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=emtricitabine+%2Ftenofovir+DF", "query": { "intervention": "emtricitabine /tenofovir DF" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 338, "total_pages": 34, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=emtricitabine+%2Ftenofovir+DF&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T16:18:36.487Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02652624", "title": "Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "E/C/F/TDF", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 472, "start_date": "2016-02-19", "completion_date": "2018-11-26", "has_results": true, "last_update_posted_date": "2020-03-04", "last_synced_at": "2026-09-29T16:18:36.487Z", "location_count": 29, "location_summary": "Stamford, Connecticut • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 22 more", "locations": [ { "city": "Stamford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Ft. Pierce", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02652624" }, { "nct_id": "NCT00105079", "title": "GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "saquinavir [Invirase]", "type": "DRUG" }, { "name": "Lopinavir/ritonavir", "type": "DRUG" }, { "name": "Emtricitabine/tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 337, "start_date": "2005-04", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2011-11-02", "last_synced_at": "2026-09-29T16:18:36.487Z", "location_count": 19, "location_summary": "Hobson City, Alabama • Tucson, Arizona • Berkeley, California + 16 more", "locations": [ { "city": "Hobson City", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00105079" }, { "nct_id": "NCT01252940", "title": "Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "FTC/RPV/TDF", "type": "DRUG" }, { "name": "PI", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "NRTIs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 482, "start_date": "2010-11", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2015-12-04", "last_synced_at": "2026-09-29T16:18:36.487Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01252940" }, { "nct_id": "NCT05072093", "title": "Parrying the Pitfalls of PrEP: Project PEACH", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV", "STI" ], "interventions": [ { "name": "PrEP discontinuation intervention", "type": "BEHAVIORAL" }, { "name": "Offering of on-demand oral PrEP", "type": "DRUG" }, { "name": "Offering of STI PEP", "type": "DRUG" }, { "name": "Injectable PrEP", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 240, "start_date": "2021-11-20", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-09-29T16:18:36.487Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05072093" }, { "nct_id": "NCT00117676", "title": "A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "TDF", "type": "DRUG" }, { "name": "ADV", "type": "DRUG" }, { "name": "TDF placebo", "type": "DRUG" }, { "name": "ADV placebo", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 382, "start_date": "2005-02", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2017-03-07", "last_synced_at": "2026-09-29T16:18:36.487Z", "location_count": 17, "location_summary": "La Jolla, California • Pasadena, California • San Diego, California + 12 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00117676" }, { "nct_id": "NCT00949234", "title": "Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Prevention", "HIV Infections" ], "interventions": [ { "name": "tenofovir + emtricitabine, lopinavir/ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 267, "start_date": "2010-03", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2017-12-18", "last_synced_at": "2026-09-29T16:18:36.487Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00949234" }, { "nct_id": "NCT03387462", "title": "DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Adherence, Medication", "Risk Behavior", "Pre-Exposure Prophylaxis", "HIV Prevention" ], "interventions": [ { "name": "Emtricitabine / Tenofovir Disoproxil Oral Tablet", "type": "DRUG" }, { "name": "DOT Diary mobile app", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Public Health Foundation Enterprises, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "18 Years to 35 Years" }, "enrollment_count": 20, "start_date": "2018-02-28", "completion_date": "2018-08-30", "has_results": true, "last_update_posted_date": "2021-10-27", "last_synced_at": "2026-09-29T16:18:36.487Z", "location_count": 2, "location_summary": "San Francisco, California • Atlanta, Georgia", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03387462" }, { "nct_id": "NCT02638493", "title": "The Compartmental Biology of HIV in the Male Genital Tract", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Human Immunodeficiency Virus", "Virus Shedding" ], "interventions": [], "intervention_types": [], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "MALE", "summary": "18 Years to 60 Years · Male only" }, "enrollment_count": 26, "start_date": "2015-12", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2017-07-24", "last_synced_at": "2026-09-29T16:18:36.487Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02638493" }, { "nct_id": "NCT01293123", "title": "Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Raltegravir", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 2, "start_date": "2011-12", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2019-10-31", "last_synced_at": "2026-09-29T16:18:36.487Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01293123" }, { "nct_id": "NCT01533259", "title": "Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "Stribild", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2012-01", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2015-01-26", "last_synced_at": "2026-09-29T16:18:36.487Z", "location_count": 9, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01533259" } ] }